Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Hauls Back Mid-Term Profit Outlook As It Builds Oncology

Executive Summary

Big cut in mid-term profit outlook hits Daiichi Sankyo shares but company says it is reallocating more to R&D to accelerate the strategic build-out of its oncology franchise.

You may also be interested in...



Penalty For Daiichi As It Falls Short In Japan Flu Vaccine Project

Japanese firm fails to meet production capacity target under Japan national flu vaccine supply plan, triggering a financial penalty and the return of government grant money.

Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Oncology news and highlights from our US FDA Performance Tracker.

Daiichi Taps AnHeart As It Focuses Oncology Push

As part of its strategic pivot towards oncology, Daiichi Sankyo reaches a global out-licensing deal with a little-known US venture for an early-stage asset, which also hints at where its priorities lie.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel